Illumina Inc. (ILMN): Today's Featured Drugs Loser

Illumina ( ILMN) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1%. By the end of trading, Illumina fell 66 cents (-1.7%) to $39.18 on light volume. Throughout the day, 636,868 shares of Illumina exchanged hands as compared to its average daily volume of 2.8 million shares. The stock ranged in price between $38.90-$39.98 after having opened the day at $39.97 as compared to the previous trading day's close of $39.84. Other company's within the Drugs industry that declined today were: Prima Biomed Ltd. ADR ( PBMD), down 22.1%, Telik ( TELK), down 20.3%, Medgenics ( MDGN), down 11.8%, and Celsion Corporation ( CLSN), down 9.3%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $4.96 billion and is part of the health care sector. The company has a P/E ratio of 61.5, above the average drugs industry P/E ratio of 60.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 30.7% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Illumina a buy, one analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation.

On the positive front, Supernus Pharmaceuticals ( SUPN), up 114.2%, Aoxing Pharmaceutical Company ( AXN), up 24.6%, pSivida ( PSDV), up 19.7%, and GTx ( GTXI), up 19%, were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer on the Problem With the Case for More Rate Hikes

Jim Cramer on the Problem With the Case for More Rate Hikes

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low